J&J: Sirturo significantly improved treatment outcomes in patients with rifampicin-resistant tuberculosis.
83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control ...
Tag: johnson and johnson
Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination ...
